FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143459396> ?p ?o ?g. }

• W2143459396 endingPage "5464" @default.
• W2143459396 startingPage "5449" @default.
• W2143459396 abstract "// Renaud Sabatier 1,2,3 , Pascal Finetti 1 , Emilie Mamessier 1 , José Adelaide 1 , Max Chaffanet 1 , Hamid Raza Ali 4,5 , Patrice Viens 1,2,3 , Carlos Caldas 5 , Daniel Birnbaum 1 and François Bertucci 1,2,3 1 Département d’Oncologie Moléculaire, “Equipe labellisée Ligue Contre le Cancer”, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, INSERM UMR1068, CNRS UMR725, Marseille, France 2 Département d’Oncologie Médicale, CRCM, Institut Paoli-Calmettes, Marseille, France 3 Faculté de Médecine, Aix-Marseille Université, Marseille, France 4 Department of Pathology, University of Cambridge, Cambridge, United Kingdom 5 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom Correspondence: François Bertucci, email: // Keywords : breast cancer, chemotherapy, immune response, PDL1, survival Received : November 17, 2014 Accepted : December 26, 2014 Published : December 31, 2014 Abstract Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different carcinomas with correlation between PDL1 tumor expression and responses. We retrospectively analyzed PDL1 mRNA expression in 45 breast cancer cell lines and 5,454 breast cancers profiled using DNA microarrays. Compared to normal breast samples, PDL1 expression was upregulated in 20% of clinical samples and 38% of basal tumors. High expression was associated with poor-prognosis features (large tumor size, high grade, ER-negative, PR-negative, ERBB2- positive status, high proliferation, basal and ERBB2 -enriched subtypes). PDL1 upregulation was associated with biological signs of strong cytotoxic local immune response. PDL1 upregulation was not associated with survival in the whole population, but was associated with better metastasis-free and overall specific survivals in basal tumors, independently of clinicopathological features. Pathological complete response after neoadjuvant chemotherapy was higher in case of PDL1 upregulation (50% versus 21%). In conclusion, PDL1 upregulation, more frequent in basal breast cancers, was associated with increased T-cell cytotoxic immune response. In this aggressive subtype, upregulation was associated with better survival and response to chemotherapy. Reactivation of dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent promising strategy in PDL1-upregulated basal breast cancer." @default.
• W2143459396 created "2016-06-24" @default.
• W2143459396 creator A5009364522 @default.
• W2143459396 creator A5011899504 @default.
• W2143459396 creator A5033716671 @default.
• W2143459396 creator A5041163775 @default.
• W2143459396 creator A5052720571 @default.
• W2143459396 creator A5053713474 @default.
• W2143459396 creator A5075116389 @default.
• W2143459396 creator A5084660376 @default.
• W2143459396 creator A5089060804 @default.
• W2143459396 creator A5091721810 @default.
• W2143459396 date "2014-12-31" @default.
• W2143459396 modified "2023-10-17" @default.
• W2143459396 title "Prognostic and predictive value of PDL1 expression in breast cancer" @default.
• W2143459396 cites W1968154499 @default.
• W2143459396 cites W1971208896 @default.
• W2143459396 cites W1975401903 @default.
• W2143459396 cites W1976173969 @default.
• W2143459396 cites W1978857579 @default.
• W2143459396 cites W1980023088 @default.
• W2143459396 cites W1987123970 @default.
• W2143459396 cites W1990779902 @default.
• W2143459396 cites W1994238092 @default.
• W2143459396 cites W1998810112 @default.
• W2143459396 cites W2000895026 @default.
• W2143459396 cites W2004241887 @default.
• W2143459396 cites W2005895632 @default.
• W2143459396 cites W2007916488 @default.
• W2143459396 cites W2007997332 @default.
• W2143459396 cites W2009098155 @default.
• W2143459396 cites W2016732129 @default.
• W2143459396 cites W2016789384 @default.
• W2143459396 cites W2016983859 @default.
• W2143459396 cites W2018020283 @default.
• W2143459396 cites W2020016182 @default.
• W2143459396 cites W2031659092 @default.
• W2143459396 cites W2032900167 @default.
• W2143459396 cites W2033672531 @default.
• W2143459396 cites W2036905020 @default.
• W2143459396 cites W2039123767 @default.
• W2143459396 cites W2044702943 @default.
• W2143459396 cites W2050999762 @default.
• W2143459396 cites W2053122486 @default.
• W2143459396 cites W2057186227 @default.
• W2143459396 cites W2058941227 @default.
• W2143459396 cites W2062963786 @default.
• W2143459396 cites W2063264144 @default.
• W2143459396 cites W2071606440 @default.
• W2143459396 cites W2073049760 @default.
• W2143459396 cites W2082431132 @default.
• W2143459396 cites W2096283457 @default.
• W2143459396 cites W2099175643 @default.
• W2143459396 cites W2099751212 @default.
• W2143459396 cites W2100413206 @default.
• W2143459396 cites W2101017424 @default.
• W2143459396 cites W2101653483 @default.
• W2143459396 cites W2102575291 @default.
• W2143459396 cites W2108933323 @default.
• W2143459396 cites W2109485845 @default.
• W2143459396 cites W2109761866 @default.
• W2143459396 cites W2112434826 @default.
• W2143459396 cites W2112648444 @default.
• W2143459396 cites W2112927491 @default.
• W2143459396 cites W2120261416 @default.
• W2143459396 cites W2124427232 @default.
• W2143459396 cites W2130207101 @default.
• W2143459396 cites W2130598050 @default.
• W2143459396 cites W2132619562 @default.
• W2143459396 cites W2134539328 @default.
• W2143459396 cites W2134878729 @default.
• W2143459396 cites W2136313650 @default.
• W2143459396 cites W2136731993 @default.
• W2143459396 cites W2138286889 @default.
• W2143459396 cites W2143186560 @default.
• W2143459396 cites W2144855008 @default.
• W2143459396 cites W2150757282 @default.
• W2143459396 cites W2153454576 @default.
• W2143459396 cites W2157058802 @default.
• W2143459396 cites W2158348986 @default.
• W2143459396 cites W2160834915 @default.
• W2143459396 cites W2161558877 @default.
• W2143459396 cites W2169360530 @default.
• W2143459396 cites W2170989872 @default.
• W2143459396 cites W2171480930 @default.
• W2143459396 cites W2560367415 @default.
• W2143459396 cites W3148605447 @default.
• W2143459396 cites W4230861071 @default.
• W2143459396 doi "https://doi.org/10.18632/oncotarget.3216" @default.
• W2143459396 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4467160" @default.
• W2143459396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25669979" @default.
• W2143459396 hasPublicationYear "2014" @default.
• W2143459396 type Work @default.
• W2143459396 sameAs 2143459396 @default.
• W2143459396 citedByCount "397" @default.
• W2143459396 countsByYear W21434593962015 @default.
• W2143459396 countsByYear W21434593962016 @default.
• W2143459396 countsByYear W21434593962017 @default.

• next